Safety and Tolerability of Intravenous Administration of ICVB-1042

ClinicalTrials.gov ID: NCT05904236

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05904236. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Study to evaluate the safety and tolerability of intravenous ICVB-1042

Study identification

NCT ID: NCT05904236
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: IconOVir Bio; Industry
Enrollment: 17 participants

Conditions and interventions

Conditions

Patients With Advanced Solid Tumors

Interventions

Treatment with ICVB-1042 administered intravenously Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 1, 2023 (Actual)
Primary completion: Dec 11, 2024 (Actual)
Completion: Dec 20, 2024 (Actual)
Last update posted: Apr 8, 2025

2023 – 2024

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
California Cancer Associates	San Marcos	California	92069	—
Karmanos Cancer Institute	Detroit	Michigan	48201	—
NYU Langone Health, Perlmutter Cancer Center	New York	New York	10016	—
University of North Carolina Lineberger Comprehensive Cancer Center	Chapel Hill	North Carolina	27599	—
Carolina BioOncology	Huntersville	North Carolina	28078	—
University of Pennsylvania, Abramson Cancer Center	Philadelphia	Pennsylvania	19104	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
Next Oncology, Dallas	Irving	Texas	75039	—
Next Oncology, San Antonio	San Antonio	Texas	78229	—
Next Oncology, Virginia	Fairfax	Virginia	22031	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05904236, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 8, 2025 · Synced Nov 14, 2026